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ABSTRACT  
The aim of the present study was to formulate, develop and evaluate ophthalmic solution containing Tafluprost. The selected prostaglandin 
analogue belongs to BCS - II. So to increase the solubility of the Tafluprost in WFI Beta Cyclodextrin was used by performing various trials 
variables of the experiments procedure Stirring time and speed were optimized to enhance the solubility. From the experimental procedure 
with different trails 20mg/mL of Cyclodextrins was fixed for the optimized formula. The product were characterized for appearance, physical 
state, colour and odour of the drug characteristics. The prepared formulations were evaluated for pH, osmolality and assay and found to be in 
acceptable ranges. Stability study was carried out for optimized formulation at 40°C±2°C /NMT 25%RH and 30°C ±2°C/ 65%±5% RH for 3 
months, were evaluated for pH ,osmolality ,assay found to be within  acceptable limits. Finally it can be concluded that the in house product 
Tafluprost ophthalmic solution was met with in the specification. 
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Ophthalmic preparations are specialized dosage forms 
designed to be instilled onto the external surface of eye 
(topical), administered inside (intraocular), adjacent to the 
eye (periocular) or used in conjunction with any special 
device1. 
Ocular drug delivery is one of the most appealing and 
arduous endeavours facing by the pharmaceutical scientist. 
The primitive ophthalmic solutions, suspensions and 
ointment dosage forms are unquestionably no longer 
satisfactory to combat some current virulent diseases2, 3. An 
analysis write-up proclaims that almost 90% of ready for 
use ophthalmic formulations in the US, and an equivalent 
percentage is still supposedly valid for the present 
international trade. 
On the ground of anatomy and physiology eye is a complex 
and incomparable structure guarded by a number of 
defensive attitude machineries. The framework, 
biochemistry, and physiology of the eye set down this organ 
tremendously impervious to strange entities4. Assorted 
adaptations guarding the eye from noxious entities and 
agents such as lacrimation, reflex blinking, rapid tear 
turnover, drainage, and pre-corneal loss concludes in 
remarkably inadequate absorption of topically executed 
ophthalmic drugs. 
Development of newer, more sensitive diagnostic techniques 
and novel therapeutic agents continue to provide ocular 
delivery systems with high therapeutic efficacy. 
Conventional ophthalmic formulations like solution, 
suspension, and ointment have many disadvantages, which 
result into poor bioavailability of drug in the ocular cavity. 
The specific aim of designing a therapeutic system is to 
achieve an optimal concentration of a drug at the active site 
for the appropriate duration1. 
Prostaglandins analogues are main playing important role in 
ophthalmic eye formulations. It Tafluprost is used topically 
to control the progression of open angle glaucoma, 
And in the management of ocular hypertension, alone or in 
the combination with other medications. It reduces 
intraocular pressure by increasing the outflow of aqeous 
fluid from the eyes. 
Routes of Ocular Drug Delivery 
There are several possible routes of drug delivery into the 
ocular tissues. The selection of the route of administration 
depends primarily on the target tissue1. 
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Mechanism of Ocular Drug Absorption 
Corneal permeation8, 9 
 
 
The Tafluprost acid is a Prostanoid selective FP receptor 
agonist so that it is believed to reduce the intraocular 
pressure and also increasing the outflow of aqueous humor 
in the eye5, 6, 7. So that the Studies in animals and humans 
recommend mechanism of action is increased uveoscleral 
outflow10. 
MATERIALS AND METHODS: 
Tafluprost (Symbiotic), Sodium dihydrogen phosphate 
monohydrate (Merck), anhydrous disodium phosphate 
(Merck), Beta cyclodextrins (Casymchem), Benzalkonium 
chloride (Merck), Sodium Chloride (Merck) and water for 
injection (WFI) are used in the preparation of Tafluprost 
Ophthalmic Solution. All chemicals used in this study are 
analytical grade. 
Method:  
The experimental work are conducted in stages as follow_ 
Preformulation Studies: 
Physical Characterization of Active Pharmaceutical 
Ingredient (Tafluprost) was observed regarding Appearance, 
Physical state, Colour & Odour. 
 
 
Prasad et el                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(5-s):18-24 
ISSN: 2250-1177                                                                                  [20]                                                                                 CODEN (USA): JDDTAO 
Procedure for Physical Characterization of Tafluprost: 
2g of sample was taken into clean and dry petridish, spread 
uniformly with spatula and above parameters were 
observed. 
Procedure for Preparation of Tafluprost Ophthalmic 
Solution: 
Different trials were taken to optimize the method of 
preparation of Tafluprost Ophthalmic Solution which are 
mentioned in step wise as below_ 
Optimization of Osmolality: 
As per pack insert from the quantities of Tafluprost, 
Benzalkonium chloride and are listed as follows;  
Tafluprost                               : 50Mcg/mL 
Benzalkonium chloride : 0.1% 
The basis of osmolality of eye fluid (i.e; 280-320mosm/kg) 
the remaining excipients were optimized. The quantities of 
API and preservative are kept as same that of reference 
product. Different solutions with varying concentrations of 
Sodium Chloride, Sodium dihydrogen phosphate 
monohydrate, Disodium phosphate prepared and measured 
for osmolality. Experiment shows, increase or decrease of 
osmolality upon increase or decrease of quantity in 
solutions. So that the below illustrate the osmolality value 
for different trials. 
Method of Preparation for Optimization of 
concentration of osmolality agent: 
Collect approximately required quantity of Water for 
injection for batch size from that Collect 70% batch size of 
WFI in Duran bottle. To it add Sodium dihydrogen 
phosphate followed by disodium hydrogen phosphate 
anhydrous, sodium chloride & benzalkonium chloride and 
dissolve under stirring until to get clear solution. Finally add 
the batch quantity of API and stir until it get dissolve and 
make up the volume to 100% batch size. 
 
NAME OF THE INGREDIENT 
CONCENTRATION mg/mL 
Trail-1 Trail-2 Trail-3 Trail-4 
Tafluprost 0.05 0.05 0.05 0.05 
Sodium Dihydrogen phosphate monohydrate 13 8 4.6 4.6 
Disodium phosphate 12 7 4.7 4.7 
Sodium chloride(Concentration) 7 6 5.4 4.1 
BKC 0.1 0.2 0.2 0.2 
Water for Injections q.s q.s q.s q.s 
Osmolality 597.83 454.93 325.5 289.91 
pH 7.8 7.3 7 6.7 
 
Conclusion: Based on above trails, it was found that trail -4 
was meeting the requirement.so that further studies were 
carried out with the trail 4. (i.e.; 280-320mosm/kg). So 
quantification of Excipients was fixed as per trail-4.  
Optimization of API Solubility:  
Tafluprost generally belongs to BCS class 2 which is less 
soluble and high permeability drug. The proposed 
formulation in aqueous eye drop preparation. Hence water 
for injection is selected as a vehicle as already known that 
Tafluprost is practically insoluble in water (It indicates less 
than 0.1 mg/mL). 
So Hydroxy propyl Beta cyclodextrins used to improve the 
solubility of the Tafluprost in aqueous phase without 
degradation of product. The concentration of hydroxyl 
propyl beta cyclodextrins was fixed based on trial basis. 
Method of Preparation for Optimization of API 
Solubility: 
Collect Approximately 110% batch size of Water for 
injection and purge nitrogen for 30 minutes to remove 
dissolved oxygen content levels. (Limit of D.O level-Less than 
2 mg/L. Collect 70% batch size of WFI in duran bottle and 
add Hydroxypropyl betadextrins under stirring followed by 
Sodium dihydrogen phosphate, disodium hydrogen 
phosphate anhydrous and sodium chloride& benzalkonium 
chloride and dissolve under stirring until to get clear 
solution. Finally add the batch quantity of API and stir until 
it get dissolve and make up the volume to 100% batch size.
 
 
NAME OF THE INGREDIENT 
CONCENTRATION mg/mL 
Trail-5 Trail-6 Trail-7 Trail-8 
Tafluprost 0.05 0.05 0.05 0.05 
Beta cyclo dextrins 3 7 15 20 
Sodium Dihydrogen phosphate monohydrate 4.6 4.6 4.6 4.6 
Disodium phosphate 4.7 4.7 4.7 4.7 
Sodium chloride 4.1 4.1 4.1 4.1 
Benzalkonium chloride 0.1 0.1 0.1 0.1 
Water for Injections q.s q.s q.s q.s 
Assay (percentage) 40 68 94 100.2 
From the above data it was found that Trial 8was found to be better compared to other trials. Further manufacturing process 
was optimized (i.e., stirring speed and stirring time) 
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Optimisation of Manufacturing Process: 
Stirring time and speed: 
Generally stirring time and speed alter the solubility. Various 
trails were taken to optimize the solubility of the drug. 
Different batches were prepared and stirred at different 
speed on a magnetic stirrer. Time taken for solubilisation of 
Tafluprost was noted with assay. Results are as follows.
 
RPM/Time taken for 
solubilisation 
Trail-9 Trail-10 Trail-11 Trail-12 
RPM 100 150 200 250 
Time (hr) 4 4 4 6 
Assay 88.5 92.3 97.6 101.9 
 
Based on the above analytical results, as the stirring time and RPM increases the solubility also increased. It was found that the 
250 RPM for minimum 6 hours stirring shown better assay value. 
Final Optimized formula: 
S.No. Formula Quantity(mg/ml) 
1.   Tafluprost  0.05 
2.   Hydroxy propyl beta cyclodextrins 20 
3.   Sodium Dihydrogen phosphate monohydrate 4.6 
4.   Disodium phosphate 4.7 
5.   Benzalkonium chloride 0.1 
6.   Sodium chloride 4.1 
7.   Water for injection Q.S. 
 
Final Optimized Method: 
Collect Approximately 110% batch size of Water for injection 
and purge nitrogen for 30 minutes to remove dissolved 
oxygen content levels. (Limit of D.O level-Less than 2 mg/L). 
Collect 70% batch size of WFI in duran bottle to it add 
Hydroxypropyl beta dextrins in above step 2 and set 
magnetic stirrer speed 100 RPM followed by addition of 
Sodium dihydrogen phosphate, disodium hydrogen 
phosphate anhydrous & Sodium chloride and stir until it get 
dissolve. From the above solution 30 % of total batch size of 
above solution in a beaker and add batch quantity of API and 
stir to get dissolve. To the remaining solution add 
benzalkonium chloride which have been dissolved in water 
and stir to get dissolve. API containing solution was added to 
benzalkonium chloride solution and stirred for 4 hrs and 
makeup the solution 100% batch size. Same process and 





Trail-13 Trail-14 Trail-15 Trail-16 
1.  Tafluprost 0.05 0.05 0.05 0.05 
2.  Hydroxy propyl beta cyclodextrins 20 20 20 20 
3.  Sodium Dihydrogen phosphate monohydrate 4.6 4.6 4.6 4.6 
4.  Disodium phosphate 4.7 4.7 4.7 4.7 
5.  Benzalkonium chloride 0.1 0.1 0.1 0.1 
6.  Sodium chloride 4.1 4.1 4.1 4.1 
7.  Water for injection q.s q.s q.s q.s 
 
RESULTS AND DISCUSSION 
Appearance: 
All the formulation batches of tafluprost ophthalmic solution 
were found to be Clear Colourless solution.  
Drug Content:  
The drug content was found to be in acceptable range for all 
the formulations in the initial. 
The in process specification 95%-105% and tafluprost 
ophthalmic solution was found with in the limit and the 
results are tabulated below. 
Osmolality: 
The Osmolality of all formulation was found to be 
satisfactory and was in the range and the data was found 
mentioned in the below table.. 
pH: 
The pH of all formulations was found to be satisfactory and 
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Batch No 
Test Parameter 
Drug Content Osmolality (m Osm/kg) pH 
F1 (Initial) 105.4 289 6.72 
F2 (Initial) 103.6 290 6.73 
F3 (Initial) 104.1 289 6.72 
 
Viscosity Study: The tafluprost ophthalmic solution shown 
data tabulated in the below from the initial  to 40°C±2°C 
/NMT25%RH up to 3 months in the accelerated condition. 
There is no significant changes observed from the initial to 3 
months. So that the product is stable up to 3 months.
 
Viscosity 
Batch No Condition  Results 
F1( 715/051A) Initial 2 cps 
F1( 715/051B) Initial 3 cps 
F2( 715/039) Initial 2 cps 
F1( 715/051A) 40/25 3M 2 cps 
F1( 715/051B) 40/25 3M 3 cps 
F2( 715/039) 40/25 3M 2 cps 
 
 Drop Size: 
The Drop size of the Tafluprost ophthalmic solution was performed formed the results in the below table: 
Calculation of the drop size 
Drop size in µL = Average Wt .of drops(mg)/Density of the solution 
S.No TEST PARAMETER 
Weight of the Drop (mg) 
Orientation 
Inverted 90° Inclined 45° 
1 
DROP SIZE STUDY 
48.63 35.95 
2 49.05 37.21 
3 48.54 37.36 
4 49.18 37.31 
5 48.25 34.45 
6 49.01 38.68 
7 49.79 38.57 
8 47.65 38.49 
9 47.98 37.71 
10 48.65 37.24 
11 48.43 37.36 
12 47.99 39.58 
13 48.12 37.95 
14 47.65 38.66 
15 49.42 38.36 
16 48.15 38.2 
17 47.77 38.34 
18 47.65 37.82 
19 49.02 38.42 
20 47.75 37.89 
21 48.24 37.89 
22 48.01 37.36 
23 48.91 37.18 
24 48.06 38.84 
25 47.78 38.8 
26 48.11 38.31 
27 47.8 38.01 
28 47.95 39.49 
29 47.94 37.72 
30 47.95 38.28 
Total weight(mg) 1449.43 1137.43 
Average weight of 30 Drops(mg) 48.31 37.91 
Density of the solution 1.0058 1.0059 
Drop Size (µL) 48.04 37.69 
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Stability Study: 
Prepared formulations Anti-Glaucomal ophthalmic solution 
was subjected to pH stability and containers compatibility 
studies at 40°C ± 2 °C /NMT 25% , for a period of 1 month,2 
and 3 months. From the above data 3-piece LDPE container 
was better compatible with formulation. Also the pH 
remained within desired range for 3-piece LDPE containers. 
Also prepared formulations of Anti-Glaucomal ophthalmic 
solution was subjected to stability studies at 30°C ± 2 °C 
/65% ± 5 % RH for a period of 1 month, 2 month and 3 
month as per ICH guidelines. The samples were withdrawn 
after period of 1 month, 2 month and 3 month and were 
evaluated for following parameters such as Description, Drug 
content, pH, and Osmolality as given in table. 
   
STABILITY RESULT OF BATCH NO F1 (715/051A) 
Stability Condition 
Initial 
40°C±2°C /NMT25%RH 30°C ±2°C/ 65%±5%RH 
Test parameters 1M 2M 3M 1M 2M 3M 
Description # # # # # # # 
Assay of API (%) 105.4 103.6 104.1 103.7 103.2 105.4 107.3 
pH 6.72 6.73 6.74 6.71 6.72 6.74 6.72 
Osmolality (mOsm/kg) 272 273 267 291 262 277 289 
 
STABILITY STUDY STABILITY RESULT OF BATCH NO-F1 (715/051B) 
Stability Condition 
Initial 
40°C±2°C /NMT25%RH 30°C ±2°C/ 65%±5%RH 
Test parameters 1M 2M 3M 1M 2M 3M 
Description # # # # # # # 
Assay of API (%) 105.4 98.5 96.6 95.7 102.2 98.4 107.6 
pH 6.71 6.72 6.74 6.73 6.72 6.74 6.73 
Osmolality (mOsm/kg) 272 267 274 306 261 277 315 
 
STABILITY STUDY:            STABILITY RESULT OF BATCH NO- F2 ( 715/039) 
Stability Condition 
Initial 
40°C±2°C /NMT25%RH 30°C ±2°C/ 65%±5%RH 
Test parameters 1M 2M 3M 1M 2M 3M 
Description # # # # # # # 
Assay of API(%) 100.2 96.7 97.3 101.2 97.8 99.3 98.6 
pH 6.71 6.73 6.72 6.75 6.71 6.72 6.73 
Osmolality (mOsm/kg) 272 267 274 306 261 277 315 
 
The Physical parameters like Description and pH Osmolality 
was found to be satisfactory and the assay of tafluprost was 
found to be with in the Specification Limit. The above data 
represents that the Tafluprost ophthalmic solution was 
found to be stable with in respective from the initial to the 3 
months of the accelerated and long term condition. 
SUMMARY AND CONCLUSION  
Ophthalmic solutions mainly used in the Topical 
administration for the treatment of Glaucoma. So that 
Tafluprost ophthalmic solutions are mainly used for the 
treatment of the open angle Glaucoma. Tafluprost is belongs 
to BCS class II, which is having high permeability and low 
solubility. Hydroxy propyl beta cyclodextrins was used to 
enhance the solubility of Tafluprost API in the Tafluprost 
ophthalmic solution. Various trails of beta cyclodextrins 
were taken with different concentrations as the 
concentration of beta cyclodextrins increases solubility of 
the Tafluprost also increased. The concentration hydroxy 
propyl beta cyclodextrins i.e. (20mg/ml) shown 100% 
solubility in the experimental procedure. Optimization of 
Osmolality studies were done by taking various trails of 
sodium chloride with 7mg, 6mg and 4.1mg of different 
concentration used to bring the Osmolality value of lacrimal 
fluids. Finally Sodium chloride (4.1mg/mL) was 
concentration was fixed for the Tafluprost ophthalmic 
solution. Optimization of stirring speed and time studies 
were done with the various trails were taken with different 
RPM and time. As the time increases the solubility of the 
drug also increased in the Tafluprost ophthalmic solution 
stirring at 250rpm for 6 hours shown better assay value. 
Prepared formulations Tafluprost ophthalmic solution was 
subjected to pH stability and containers compatibility 
studies at40°C C ± 2 °C /NMT 25%, for a period of 1 month, 2 
and 3 months. Also prepared formulations of Tafluprost 
ophthalmic solution was subjected to stability studies at 
30°C ± 2 °C /65% ± 5 % RH for a period of 1 month, 2 month 
and 3 month as per ICH guidelines. 
The product was found to be stable and no significant chang
e was observed during the Accelerated and intermediate 
term stability conditions. There is no change in the Viscosity 
in the Tafluprost ophthalmic solution through the Stability 
period up to 3months in both the accelerated and 
intermediate term condition. Finally it is concluded that the 
product Tafluprost ophthalmic solution was met the 
specifications. 
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